Association of Tumor-infiltrating Lymphocytes With Recurrence Score in Hormone Receptor-positive/HER2-negative Breast Cancer: Analysis of Four Prospective Studies
出版年份 2023 全文链接
标题
Association of Tumor-infiltrating Lymphocytes With Recurrence Score in Hormone Receptor-positive/HER2-negative Breast Cancer: Analysis of Four Prospective Studies
作者
关键词
-
出版物
EUROPEAN JOURNAL OF CANCER
Volume -, Issue -, Pages 113399
出版商
Elsevier BV
发表日期
2023-10-27
DOI
10.1016/j.ejca.2023.113399
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update
- (2022) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor–Positive Breast Cancer
- (2022) Barbara Pistilli et al. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
- PD-L1 protein expression in relation to recurrence score values in early-stage ER + breast cancer
- (2022) Mariya Rozenblit et al. BREAST CANCER RESEARCH AND TREATMENT
- Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
- (2021) Thomas Bachelot et al. NATURE MEDICINE
- Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
- (2021) Maria Vittoria Dieci et al. Cells
- PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy
- (2021) Francesco Cognetti et al. npj Breast Cancer
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
- (2021) Lajos Pusztai et al. CANCER CELL
- Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial
- (2021) Maria Vittoria Dieci et al. CLINICAL CANCER RESEARCH
- 21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer
- (2021) Kevin Kalinsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer
- (2020) Rita Nanda et al. JAMA Oncology
- Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
- (2020) Alberto Zambelli et al. BREAST
- Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer
- (2020) C. Criscitiello et al. BREAST CANCER RESEARCH AND TREATMENT
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
- (2020) Sara M. Tolaney et al. JAMA Oncology
- Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers
- (2019) Yukie Fujimoto et al. Breast Cancer
- Impact of 21‐Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study
- (2019) Maria Vittoria Dieci et al. ONCOLOGIST
- Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer
- (2018) Sung Gwe Ahn et al. BMC CANCER
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- First Prospective Multicenter Italian Study on the Impact of the 21‐Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer
- (2017) Maria Vittoria Dieci et al. ONCOLOGIST
- The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
- (2016) Maria Vittoria Dieci et al. CANCER TREATMENT REVIEWS
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer
- (2015) Satu Tiainen et al. HISTOPATHOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- High infiltration of tumor-associated macrophages in triple-negative breast cancer is associated with a higher risk of distant metastasis
- (2014) Zhong-Yu Yuan et al. OncoTargets and Therapy
- Tumor-infiltrating lymphocytes in breast cancer
- (2014) Yasmin Issa-Nummer et al. OncoImmunology
- Prognostic Significance of Progesterone Receptor–Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
- (2012) Aleix Prat et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumour-infiltrating macrophages and clinical outcome in breast cancer
- (2011) S M A Mahmoud et al. JOURNAL OF CLINICAL PATHOLOGY
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
- (2008) Joseph A. Sparano et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now